Cardiovascular risk factor profiles and endothelial function in coronary artery disease patients treated with statins

Hypertension Research

Volumn 27, Issue 10, 2004, Pages 723-729

  Okura, Yoshifumi ^b   Takao, Makiko ^b   Zhang, Bo ^b   Nakashima, Yoshiyuki ^a   Saku, Keijiro ^b  

^a FUKUOKA DENTAL COLLEGE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Endothelium; Hypercholesterolemia; Insulin; Lipoprotein (a)

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; ANGINA PECTORIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; LIPOPROTEIN(A); MALE; MIDDLE AGED; RISK FACTORS; VASODILATION;

EID: 11044236952     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.723     Document Type: Article

References (31)

1. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471.
2. Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, Baron AD: Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997; 96: 3287-3293.
3. Vita JA, Treasure CB, Nabel EG, et al: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491-497.
4. Vogel RA: Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997; 20: 426-432.
5. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567-1572.
6. Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-638.
7. Egashira K, Hirooka Y, Kai H, et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-2524.
8. Dupuis J, Tardif JC, Cernacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3233.
9. Vita JA, Yeung AC, Winniford M, et al: Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000; 102 846-851.
10. Higashi Y, Sasaki S, Nakagawa K, et al: Sodium chloride loading does not alter endothelium-dependent vasodilation of forearm vasculature in either salt-sensitive or salt-resistant patients with essential hypertension. Hypertens Res 2001; 24: 711-716.
11. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K: Leptin causes vasodilation in humans. Hypertens Res 2002; 25: 161-165.
12. On YK, Kim CH, Oh BH, Lee MM, Park YB: Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res 2002; 25: 365-371.
13. Tagawa T, Hirooka Y, Shimokawa H, et al: Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertens Res 2002; 25: 823-829.
14. Behrendt D, Ganz P: Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-48L.
15. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge, DJ, Deanfield JE: Impairment of endothelium-dependent dilatation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest 1994; 93: 50-55.
16. Schachinger V, Halle M, Minners J, Berg A, Zeiher AM: Lipoprotein (a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 1997; 30: 927-934.
17. Okura Y, Saku K, Hirata K, et al: Serum lipoprotein (a) levels in maintenance hemodialysis patients. Nephron 1993; 65 46-50.
18. Hirata K, Kikuchi S, Saku K, et al: Apolipoprotein (a) phenotypes and serum lipoprotein (a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 1993; 44: 1062-1070.
19. Saku K, Zhang B, Liu R, Shirai K, Arakawa K: Associations among serum lipoprotein (a) levels, apolipoprotein (a) phenotypes, and myocardial infarction in patients with extremely low and high levels of serum lipoprotein (a). Jpn Circ J 1999; 63: 659-665.
20. Jonkers IJ, van de Ree MA, Smelt AH, et al: Insulin resistance but not hypertriglyceridemia per se is associated with endothelial dysfunction in chronic hypertriglyceridemia. Cardiovasc Res 2002; 53: 496-501.
21. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM: Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996; 93: 1331-1333.
22. Jenkins PJ, Harper RW, Nestel PJ: Severity of coronary atherosclerosis related to lipoprotein concentration. Br Med J 1978; 2: 388-391.
23. Abe A, Maeda S, Makino K, et al: Enzyme-linked immunosorbent assay of lipoprotein (a) in serum and cord blood. Clin Chim Acta 1988; 177: 31-40.
24. Joannides R, Haefeli WE, Linder L, et al: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-1319.
25. Koh KK, Cardillo C, Bui MN, et al: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99: 354-360.
26. De Roos NM, Bots ML, Schouten EG, Katan MB: Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: implications for experimental studies. Ultrasound Med Biol 2003; 29: 401-406.
27. Wanner C, Greiber S, Kramer-Guth A, Heinloth A, Galle J: Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein (a). Kidney Int 1997; 63 (Suppl): S102-S106.
28. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
29. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-69.
30. Scanu AM, Scandiani L: Lipoprotein (a): structure, biology, and clinical relevance. Adv Intern Med 1991; 36: 249-270.
31. Smith SC Jr, Blair SN, Bonow RO, et al: AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104: 1577-1579.